DCF方案化疗联合DC-CIK治疗晚期胃癌的临床效果  

Clinical Application and Value of DCF Chemotherapy Combined with DC-CIK in the Treatment of Advanced Gastric Cancer

作　　者：余汉霞[1] 陈绍琳[1] 蔡德栋 

机构地区：[1]湖北省十堰东风公司茅箭医院,442012

出　　处：《实用癌症杂志》2017年第9期1515-1517,共3页The Practical Journal of Cancer

摘　　要：目的探讨DCF方案化疗联合DC-CIK治疗晚期胃癌的临床应用效果。方法回顾性分析60例接受DCF方案化疗晚期胃癌患者临床资料,依据是否接受DC-CIK治疗分为观察组(25例)和对照组(35例)。比较2组患者临床疗效、治疗后免疫水平以及不良反应发生率。结果观察组患者治疗总有效率显著高于对照组(χ~2=5.126,P<0.05),观察组患者治疗后免疫细胞比例显著高于对照组患者(t=12.403、t=4.378、t=7.086、t=6.964,P均<0.01),观察组患者白细胞减少、消化道反应等不良反应发生率显著低于对照组患者(χ~2=3.863、χ~2=6.524,P均<0.05)。结论DCF方案联合DC-CIK治疗晚期胃癌可以提高临床治疗效果、增强患者免疫力并降低化疗不良反应发生率,具有临床应用价值。Objective To investigate the clinical effect of DCF chemotherapy combined with DC-CIK in the treatment of advanced gastric cancer. Methods The clinical data of 60 patients with advanced gastric cancer treated with DCF chemotherapy were retrospectively analyzed. The clinical data were divided into the observation group（ 25 cases） and the control group（ 35 cases） according to whether treated with DC-CIK treatment or not. The clinical efficacy,immune level and incidence of adverse reactions of the 2 groups were compared. Results In the observation group,the total effective rate was significantly higher than that of the control group（ χ~2= 5. 126,P〈0. 05）. After treatment,the CD3 ＋,CD4 ＋,CD8 ＋ and NK cell proportion in the observation group were significantly higher than those in the control group（ t = 12. 403,t = 4. 378,t = 7. 086,t = 6. 964,P 0. 01）. The leukocytes reduction and digestive tract reaction occurrence rate in observation group were significantly lower than those of the control group（ χ^2= 3. 863,χ^2= 6. 524,P〈0. 05）. Conclusion DCF chemotherapy combined with DC-CIK treatment can improve the clinical treatment effect of advanced gastric cancer,improve the immunity of patients and reduce the adverse reaction of chemotherapy,which has clinical application value.

关 键 词：晚期胃癌 化疗 DC-CIK生物治疗 

分 类 号：R735.2[医药卫生—肿瘤]